August 9, 2022

Second Quarter
2022 Financial Results



©2022 3D Systems, Inc. | All Rights Reserved.

3D SYSTEMS

Welcome and Participants

Dr. Jeffrey Graves
President and Chief Executive Officer

Wayne Pensky
Interim Chief Financial Officer

Andrew Johnson
Executive VP and Chief Legal Officer

Russell Johnson
VP, Treasury and Investor Relations



To participate via phone, please dial:

1-201-689-8345

©2022 3D Systems, Inc. | All Rights Reserved.

Forward Looking Statements

Certain statements made in this presentation that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward looking statements can be identified by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates” or “plans” or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management’s beliefs, assumptions and current expectations and may include comments as to the company’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the company. The factors described under the headings “Forward-Looking Statements” and “Risk Factors” in the company’s periodic filings with the Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as the date of the statement. 3D Systems undertakes no obligation to update or revise any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise, except as required by law

Further, we encourage you to review “Risk Factors” in Part 1 of our Annual Report on Form 10-K and Part II of our Quarterly Reports on Form 10-Q filed with the SEC as well as other information about us in our filings with the SEC. These are available at www.SEC.gov.

©2022 3D Systems, Inc. | All Rights Reserved.


Dr. Jeffrey Graves

President & Chief Executive Officer



©2022 3D Systems, Inc. | All Rights Reserved.

Current Business Environment











- Strong trend of **adopting production-scale Additive Manufacturing applications**
  - Industrial
  - Healthcare
  - Emerging industries
- Complex macro environment creating **near-term business headwinds**
  - Macroeconomic factors
  - Geopolitical tensions
  - Foreign exchange volatility
  - Supply chain

©2022 3D Systems, Inc. | All Rights Reserved.

Second Quarter 2022 and Recent Highlights

- **YoY revenue growth after excluding divestitures:**
  - Total company: 3.2% and 7.8% in constant currency
  - Industrial: 3.8% and 11.2% in constant currency
  - Healthcare: 2.9% and 4.7% in constant currency

- **10.4% growth for first half of year after excluding divestitures and in constant currency**

- **Reducing FY 2022 guidance**
  - Foreign exchange effect reduces revenue and inflation is increasing costs
  - Macroeconomic factors and geopolitical tensions
  - Softer discretionary spend in selected end markets
    - Elective health procedures
    - Europe and Asia Pacific manufacturers

- **Efficiency actions underway to improve results**

©2022 3D Systems, Inc. | All Rights Reserved.

Regenerative Medicine Highlights

LIFE ITSELF Conference, June 2022

Dr. Martine Rothblatt of United Therapeutics & Chuck Hull of 3D Systems unveil a 3D printed ***human lung scaffold***



3D-printed lung is most complex object ever printed

44 trillion voxels

200 million alveoli

4,000 km pulmonary capillaries

Regenerative Medicine Investment Areas

- Drug discovery
- Human lung scaffold (UT partnership)
- Non-organ human tissues


©2022 3D Systems, Inc. | All Rights Reserved.

Acquisition of dp polar

Agreement Announced

August 8, 2022

- Germany-based developer of revolutionary AM platform designed for **high-speed mass production of polymer parts**
- Print heads remain stationary above the rotating platform, **providing a continuous print process**
- Planned integration of dp polar platform with 3D Systems polymer materials and software solutions to **drive rapid adoption in production environments**
- Beta testing stage
- Acquisition expected to close in **Q4 2022**



©2022 3D Systems, Inc. | All Rights Reserved.

In Summary

- Near-term headwinds impacting 2022 outlook
- Confidence in our long-term outlook
- Investing strategically for long-term growth



Wayne Pensky

Interim CFO



©2022 3D Systems, Inc. | All Rights Reserved.

Q2 Summary

- **Q2 revenues decreased 13.8% year over year**
- **Q2 revenues excluding divestitures and in constant currency increased 7.8%**
  - **Revenues also impacted by exit from Russia and supply chain disruptions**
- **GAAP loss per share of ($0.26), includes ($0.09) from est. non-recurring legal costs & other settlements**
- **Non-GAAP loss per share* of ($0.07) vs $0.06 in Q2 2021. Decreased YoY due to:**
  - Input cost inflation
  - Recent acquisitions are mostly development stage or early commercialization
  - Higher spend on R&D and infrastructure to support growth


* See Appendix for reconciliation of GAAP and non-GAAP net loss per share.

©2022 3D Systems, Inc. | All Rights Reserved.

Revenue by Segment
(Excluding Divestitures)


$ in millions

Healthcare Revenue Q2 YoY



Slowdown in growth driven by softer demand in elective procedures.
4.7% growth in constant currency


Industrial Revenue Q2 YoY



Sixth consecutive quarter of year-over-year growth.
11.2% growth in constant currency

©2022 3D Systems, Inc. | All Rights Reserved.

Gross Profit Margin




Q2 2022 vs Q2 2021

- Increase in component costs and freight
- Impact of divestitures
- Small impact from mix

©2022 3D Systems, Inc. | All Rights Reserved.

Non-GAAP Operating Expenses Excluding Divestitures



Q2 2022 vs Q2 2021


- About half of increase is from acquisitions
- Increased R&D to enhance product portfolio
- Investing in infrastructure

See appendix for a reconciliation of non-GAAP operating expenses excluding divestitures.

©2022 3D Systems, Inc. | All Rights Reserved.

Adjusted EBITDA Margin

Defined as non-GAAP Operating Income excluding divestitures plus Depreciation divided by Revenue



Q2 2022 vs Q2 2021

- Impact from acquired businesses, most are in development stage or early commercialization
- Increased input costs
- Investments in R&D and Infrastructure

See appendix for a reconciliation of Non-GAAP Operating Income and Adjusted EBITDA.

©2022 3D Systems, Inc. | All Rights Reserved.



Strong Balance Sheet

- Ended the quarter with $638.2 million dollars of cash and short-term investments on hand
- We have sufficient cash to support organic growth, including in regenerative medicine
- Invested $83.3 million in acquisitions and investments in first half of 2022
- Anticipate taking a pause on acquisitions to make sure we focus on execution and fully integrate the recent deals we have made

©2022 3D Systems, Inc. | All Rights Reserved.

Updated 2022 Outlook

Revenue between
$530 million and $570 million

Softening demand environment and delaying of customer orders
FX impact is estimated $20 million reduction

Non-GAAP Gross Margins between
39% and 41%

Higher input costs and supply chain disruptions

Non-GAAP Operating Expenses between
$245 million and $250 million

Investments in acquired businesses, research and development, and our corporate infrastructure

©2022 3D Systems, Inc. | All Rights Reserved.

Dr. Jeffrey Graves

President & Chief Executive Officer



©2022 3D Systems, Inc. | All Rights Reserved.



Q&A Session

1-201-689-8345

©2022 3D Systems, Inc. | All Rights Reserved.

Thank You

Find out more at:

www.3dsystems.com

©2022 3D Systems, Inc. | All Rights Reserved.

Appendix

©2022 3D Systems, Inc. | All Rights Reserved.

3D SYSTEMS

Presentation of Information

3D Systems reports its financial results in accordance with GAAP. Management also reviews and reports certain non-GAAP measures, including: non-GAAP revenue excluding divestitures and on a constant currency basis (sometimes referred to as excluding divestitures and FX effects), non-GAAP Gross profit, non-GAAP Gross profit margin, non-GAAP Operating expenses, non-GAAP Operating (loss)/income, non-GAAP Interest and other income/(expense), net, non-GAAP Net income (loss), non-GAAP Basic and Diluted Income (Loss) per Share, adjusted EBITDA and adjusted EBITDA Margin. These non-GAAP measures exclude certain special items that management does not view as part of 3D Systems' underlying results as they may be highly variable, may be unusual or infrequent, are difficult to predict and can distort underlying business trends and results. Management believes that the non-GAAP measures provide useful additional insight into underlying business trends and results and provide a more meaningful comparison of period-over-period results. Additionally, management uses the non-GAAP measures for planning, forecasting and evaluating business and financial performance, including allocating resources and evaluating results relative to employee compensation targets. 3D Systems' non-GAAP measures are not calculated in accordance with or as required by GAAP and may not be calculated the same as similarly titled measures used by other companies. These non-GAAP measures should thus be considered as supplemental in nature and not considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP.

A reconciliation of GAAP to non-GAAP financial measures is provided in the accompanying schedules in the Appendix.

3D Systems does not provide forward-looking guidance for certain measures on a GAAP basis. The company is unable to provide a quantitative reconciliation of forward-looking non-GAAP gross profit margins and non-GAAP operating expenses to the most directly comparable forward-looking GAAP measures without unreasonable effort because certain items, including legal, acquisition expenses, stock-compensation expense, intangible amortization expense, restructuring expenses, and goodwill impairment, are difficult to predict and estimate. These items are inherently uncertain and depend on various factors, many of which are beyond the company's control, and as such, any associated estimate and its impact on GAAP performance could vary materially.

Non-GAAP Reconciliation – Quarter Ended June 30, 2021

(Unaudited)

(in millions, except per share data)	Three Months Ended June 30, 2021, [1]					
	GAAP	**Amortization, stock-based compensation & other**	**Legal, acquisition and divestiture - related**	**Cost optimization plan and other**	**Divestitures**	**Non-GAAP**
Revenue	**$ 162.6**	**$ —**	**$ —**	**$ —**	**$ (27.0)**	**$ 135.6**
Gross Profit	**69.0**	0.2	—	(0.3)	(12.7)	**56.2**
Gross Profit Margin	**42.4 %**				47.0 %	**41.4 %**
Operating expenses	**79.1**	(21.8)	(1.7)	(0.4)	(6.3)	**48.9**
Operating (loss) income	**(10.1)**	22.0	1.7	0.1	(6.4)	**7.3**
Interest and other income (expense), net	**(0.3)**	—	—	—	0.2	**(0.1)**
Net (loss) income	**(9.6)**	22.0	1.7	0.1	(6.2)	**8.0**
Diluted (loss) income per share	**$ (0.08)**	$ 0.18	$ 0.01	$ —	$ (0.05)	**$ 0.06**
Diluted shares outstanding	122.1					122.1

[1] Amounts in table may not foot due to rounding

Non-GAAP Reconciliation – Quarter Ended Sept. 30, 2021

(Unaudited)

(in millions, except per share data)	Three Months Ended September 30, 2021, [1]				
	GAAP	**Amortization, stock-based compensation & other**	**Legal, acquisition and divestiture - related**	**Divestitures**	**Non-GAAP**
Revenue	**$ 156.1**	$ —		$ (19.4)	**$ 136.7**
Gross Profit	**64.3**	0.4		(9.4)	**55.3**
Gross Profit Margin	**41.2 %**				**40.5 %**
Operating expenses	**81.5**	(16.1)	(11.4)	(4.7)	**49.3**
Operating (loss) income	**(17.2)**	16.5	11.4	(4.7)	**6.0**
Interest and other income (expense), net	**315.9**	—	(315.5)	0.9	**1.3**
Net (loss) income	**292.7**	16.5	(299.1)	(3.6)	**6.5**
Diluted (loss) income per share	**$ 2.34**	$ 0.13	$ (2.39)	$ (0.03)	**$ 0.05**
Diluted shares outstanding	125.3				125.3

[1] Amounts in table may not foot due to rounding

Non-GAAP Reconciliation – Quarter Ended Dec. 31, 2021

(Unaudited)

(in millions, except per share data)	Three Months Ended December 31, 2021, [1]				
	GAAP	Amortization, stock-based compensation & other	Legal, acquisition and divestiture - related	Divestitures	Non-GAAP
Revenue	$ 150.9	$ —	$ —	$ —	$ 150.9
Gross Profit	66.2	0.4	—	—	66.5
Gross Profit Margin	43.9 %				44.1 %
Operating expenses	70.1	(14.7)	(1.1)	—	54.3
Operating (loss) income	(3.8)	15.1	1.1	—	12.3
Interest and other income (expense), net	(1.8)	—	1.1	—	(0.7)
Net (loss) income	(6.20)	15.1	2.7	—	11.50
Diluted (loss) income per share	$ (0.05)	$ 0.12	$ 0.02	$ —	$ 0.09
Diluted shares outstanding	127.9				127.9

[1] Amounts in table may not foot due to rounding

Non-GAAP Reconciliation – Quarter Ended March 31, 2022

(Unaudited)

(in millions, except per share data)	Three Months Ended March 31, 2022, [1]			
	GAAP	**Amortization, stock-based compensation & other**	**Legal, acquisition and divestiture - related**	**Non-GAAP**
Revenue	**$ 133.0**	$ —		**$ 133.0**
Gross Profit	**53.8**	0.1		**53.9**
Gross Profit Margin	**40.4%**			**40.6%**
Operating expenses	**77.0**	(15.2)	(4.0)	**57.8**
Operating (loss) income	**(23.2)**	15.3	4.0	**(3.9)**
Interest and other income (expense), net	**(2.3)**	—	0.3	**(2.0)**
Net (loss) income	**(26.8)**	15.3	4.3	**(7.2)**
Diluted (loss) income per share	**$ (0.21)**	$ 0.12	$ 0.03	**$ (0.06)**
Diluted shares outstanding	126.7			126.7

[1] Amounts in table may not foot due to rounding

Non-GAAP Reconciliation – Quarter Ended June 30, 2022

(Unaudited)

(in millions, except per share data)	Three Months Ended June 30, 2022, [1]			
	GAAP	**Amortization, stock-based compensation & other**	**Legal, acquisition and divestiture - related [2]**	**Non-GAAP**
Revenue	**$ 140.0**	$ —	$ —	**$ 140.0**
Gross Profit	**53.1**	0.1	—	**53.3**
Gross Profit Margin	**37.9%**			**38.1%**
Operating expenses	**85.2**	(12.6)	(11.7)	**60.9**
Operating (loss) income	**(32.0)**	12.7	11.7	**(7.6)**
Interest and other income (expense), net	**0.3**	—	0.1	**0.4**
Net (loss) income	**(33.0)**	12.7	11.8	**(8.5)**
Diluted (loss) income per share	**$ (0.26)**	$ 0.10	$ 0.09	**$ (0.07)**
Diluted shares outstanding	127.7			127.7

[1] Amounts in table may not foot due to rounding

[2] Included are $11.0 million of estimated costs for legal and other settlements

Non-GAAP Operating Income to Adjusted EBITDA Reconciliation

(in millions)	Q2-2021	Q3-2021	Q4-2021	Q1-2022	Q2-2022
Revenue - 2021 excludes revenue from divestitures	$ 135.6	$ 136.7	$ 150.9	$ 133.0	$ 140.0
Non-GAAP Operating (loss) income	7.3	6.0	12.3	(3.9)	(7.6)
Depreciation	5.6	5.6	5.6	5.8	5.0
Adjusted EBITDA	$ 12.9	$ 11.6	$ 17.9	$ 1.9	$ (2.6)
Adjusted EBITDA Margin	9.6 %	8.4 %	11.9 %	1.4 %	(1.9)%

(1)Amounts in table may not foot due to rounding

Reconciliation of Revenue to Non-GAAP Revenue[1] (in Millions, Unaudited)

	Three Months Ended June 30, 2022	Three Month Ended June 30, 2021	% Change	Constant Currency [2]		
				FX Effect [3]	2021	B(W)%
Revenue, as reported						
Healthcare	$ 71.7	$ 82.8	(13.4)%			
Industrial	68.3	79.7	(14.3)%			
Total Revenue, as reported	**$ 140.0**	**$ 162.6**	(13.8)%			
Revenue From Divestitures:						
Healthcare	$ —	$ 13.1				
Industrial	—	13.9				
Total Revenue	**$ —**	**$ 27.0**				
Total Revenue (Excl. Divest. and FX Effect):						
Healthcare	$ 71.7	$ 69.7	2.9 %	$ (1.2)	$ 68.5	4.7 %
Industrial	68.3	65.8	3.8 %	(4.4)	61.4	11.2 %
Total Revenue (Excl. Divest. and FX Effect):	**$ 140.0**	**$ 135.6**	**3.2 %**	**$ (5.6)**	**$ 129.9**	**7.8 %**

(1) Amounts in table may not foot due to rounding

(2) To assist in the analysis of the Company's revenue trends, the company estimated the impact of foreign exchange on year over year revenue growth by recasting revenue, excluding divestitures, for the three and six months ended June 30, 2021 by applying the foreign exchange rates used to translate 2022 non-US functional currency revenue to 2021 non-US functional currency revenue.

(3) FX effect is the estimated impact on "as reported" net revenue due to changes in foreign currency exchange rates

Reconciliation of Revenue to Non-GAAP Revenue[1] (in Millions, Unaudited)

	Six Months Ended June 30, 2022	Six Months Ended June 30, 2021	% Change	Constant Currency [2]		
				FX Effect [3]	2021	B(W)%
Revenue, as reported						
Healthcare	$ 136.1	$ 155.3	(12.4)%			
Industrial	136.9	153.3	(10.7)%			
Total Revenue, as reported	**$ 273.0**	**$ 308.6**	(11.5)%			
Revenue From Divestitures:						
Healthcare	$ —	$ 24.1				
Industrial		28.1				
Total Revenue	**$ —**	**$ 52.2**				
Total Revenue (Excl. Divest. and FX Effect):						
Healthcare	$ 136.1	$ 131.2	3.7 %	$ (2.3)	$ 128.9	5.6 %
Industrial	136.9	125.2	9.3 %	(6.9)	118.3	15.7 %
Total Revenue (Excl. Divest. and FX Effect):	**$ 273.0**	**$ 256.4**	**6.5 %**	**$ (9.2)**	**$ 247.2**	**10.4 %**

[1] Amounts in table may not foot due to rounding

[2] To assist in the analysis of the Company's revenue trends, the company estimated the impact of foreign exchange on year over year revenue growth by recasting revenue, excluding divestitures, for the three and six months ended June 30, 2021 by applying the foreign exchange rates used to translate 2022 non-US functional currency revenue to 2021 non-US functional currency revenue.

[3] FX effect is the estimated impact on "as reported" net revenue due to changes in foreign currency exchange rates